A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer
Abstract Background The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of diagnosis have limitations to accurately establish progression ris...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5592-6 |
| _version_ | 1818544148006830080 |
|---|---|
| author | Constantin Georgescu Joshua M. Corbin Sandra Thibivilliers Zachary D. Webb Yan D. Zhao Jan Koster Kar-Ming Fung Adam S. Asch Jonathan D. Wren Maria J. Ruiz-Echevarría |
| author_facet | Constantin Georgescu Joshua M. Corbin Sandra Thibivilliers Zachary D. Webb Yan D. Zhao Jan Koster Kar-Ming Fung Adam S. Asch Jonathan D. Wren Maria J. Ruiz-Echevarría |
| author_sort | Constantin Georgescu |
| collection | DOAJ |
| description | Abstract Background The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of diagnosis have limitations to accurately establish progression risk. Here we describe the development of a tumor suppressor regulated, cell-cycle gene expression based prognostic signature for PCa, and validate its independent contribution to risk stratification in several radical prostatectomy (RP) patient cohorts. Methods We used RNA interference experiments in PCa cell lines to identify a gene expression based gene signature associated with Tmeff2, an androgen regulated, tumor suppressor gene whose expression shows remarkable heterogeneity in PCa. Gene expression was confirmed by qRT-PCR. Correlation of the signature with disease outcome (time to recurrence) was retrospectively evaluated in four geographically different cohorts of patients that underwent RP (834 samples), using multivariate logistical regression analysis. Multivariate analyses were adjusted for standard clinicopathological variables. Performance of the signature was compared to previously described gene expression based signatures using the SigCheck software. Results Low levels of TMEFF2 mRNA significantly (p < 0.0001) correlated with reduced disease-free survival (DFS) in patients from the Memorial Sloan Kettering Cancer Center (MSKCC) dataset. We identified a panel of 11 TMEFF2 regulated cell cycle related genes (TMCC11), with strong prognostic value. TMCC11 expression was significantly associated with time to recurrence after prostatectomy in four geographically different patient cohorts (2.9 ≤ HR ≥ 4.1; p ≤ 0.002), served as an independent indicator of poor prognosis in the four RP cohorts (1.96 ≤ HR ≥ 4.28; p ≤ 0.032) and improved the prognostic value of standard clinicopathological markers. The prognostic ability of TMCC11 panel exceeded previously published oncogenic gene signatures (p = 0.00017). Conclusions This study provides evidence that the TMCC11 gene signature is a robust independent prognostic marker for PCa, reveals the value of using highly heterogeneously expressed genes, like Tmeff2, as guides to discover prognostic indicators, and suggests the possibility that low Tmeff2 expression marks a distinct subclass of PCa. |
| first_indexed | 2024-12-11T22:44:40Z |
| format | Article |
| id | doaj.art-7e9ac0c4083a40768ff6d2ebaf0c452b |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T22:44:40Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-7e9ac0c4083a40768ff6d2ebaf0c452b2022-12-22T00:47:39ZengBMCBMC Cancer1471-24072019-05-0119111310.1186/s12885-019-5592-6A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancerConstantin Georgescu0Joshua M. Corbin1Sandra Thibivilliers2Zachary D. Webb3Yan D. Zhao4Jan Koster5Kar-Ming Fung6Adam S. Asch7Jonathan D. Wren8Maria J. Ruiz-Echevarría9Arthritis & Clinical Immunology Program, Division of Genomics and Data Sciences, Oklahoma Medical Research FoundationDepartment of Pathology, Oklahoma University Health Sciences CenterStephenson Cancer CenterDepartment of Pathology, Oklahoma University Health Sciences CenterDepartment of Biostatistics and Epidemiology, Oklahoma University Health Sciences CenterAmsterdam UMC, Department of Oncogenomics, University of AmsterdamDepartment of Pathology, Oklahoma University Health Sciences CenterStephenson Cancer CenterArthritis & Clinical Immunology Program, Division of Genomics and Data Sciences, Oklahoma Medical Research FoundationDepartment of Pathology, Oklahoma University Health Sciences CenterAbstract Background The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of diagnosis have limitations to accurately establish progression risk. Here we describe the development of a tumor suppressor regulated, cell-cycle gene expression based prognostic signature for PCa, and validate its independent contribution to risk stratification in several radical prostatectomy (RP) patient cohorts. Methods We used RNA interference experiments in PCa cell lines to identify a gene expression based gene signature associated with Tmeff2, an androgen regulated, tumor suppressor gene whose expression shows remarkable heterogeneity in PCa. Gene expression was confirmed by qRT-PCR. Correlation of the signature with disease outcome (time to recurrence) was retrospectively evaluated in four geographically different cohorts of patients that underwent RP (834 samples), using multivariate logistical regression analysis. Multivariate analyses were adjusted for standard clinicopathological variables. Performance of the signature was compared to previously described gene expression based signatures using the SigCheck software. Results Low levels of TMEFF2 mRNA significantly (p < 0.0001) correlated with reduced disease-free survival (DFS) in patients from the Memorial Sloan Kettering Cancer Center (MSKCC) dataset. We identified a panel of 11 TMEFF2 regulated cell cycle related genes (TMCC11), with strong prognostic value. TMCC11 expression was significantly associated with time to recurrence after prostatectomy in four geographically different patient cohorts (2.9 ≤ HR ≥ 4.1; p ≤ 0.002), served as an independent indicator of poor prognosis in the four RP cohorts (1.96 ≤ HR ≥ 4.28; p ≤ 0.032) and improved the prognostic value of standard clinicopathological markers. The prognostic ability of TMCC11 panel exceeded previously published oncogenic gene signatures (p = 0.00017). Conclusions This study provides evidence that the TMCC11 gene signature is a robust independent prognostic marker for PCa, reveals the value of using highly heterogeneously expressed genes, like Tmeff2, as guides to discover prognostic indicators, and suggests the possibility that low Tmeff2 expression marks a distinct subclass of PCa.http://link.springer.com/article/10.1186/s12885-019-5592-6Prostate cancerPrognostic markersCell cycle genesRisk stratificationTMEFF2 |
| spellingShingle | Constantin Georgescu Joshua M. Corbin Sandra Thibivilliers Zachary D. Webb Yan D. Zhao Jan Koster Kar-Ming Fung Adam S. Asch Jonathan D. Wren Maria J. Ruiz-Echevarría A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer BMC Cancer Prostate cancer Prognostic markers Cell cycle genes Risk stratification TMEFF2 |
| title | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| title_full | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| title_fullStr | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| title_full_unstemmed | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| title_short | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| title_sort | tmeff2 regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer |
| topic | Prostate cancer Prognostic markers Cell cycle genes Risk stratification TMEFF2 |
| url | http://link.springer.com/article/10.1186/s12885-019-5592-6 |
| work_keys_str_mv | AT constantingeorgescu atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT joshuamcorbin atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT sandrathibivilliers atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT zacharydwebb atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT yandzhao atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT jankoster atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT karmingfung atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT adamsasch atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT jonathandwren atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT mariajruizechevarria atmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT constantingeorgescu tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT joshuamcorbin tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT sandrathibivilliers tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT zacharydwebb tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT yandzhao tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT jankoster tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT karmingfung tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT adamsasch tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT jonathandwren tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer AT mariajruizechevarria tmeff2regulatedcellcyclederivedgenesignatureisprognosticofrecurrenceriskinprostatecancer |